Jichlinski P et al., 2001-12: Review of bladder-cancer photodynamic therapy describing why the technique never gained wide acceptance, and naming ALA-induced protoporphyrin IX and hypericin as the newer photosensitisers. Methylene blue is not among them.
the 25 years of experience combined with the recent discovery of new photosensitisers, such as protoporphyrin IX (PpIX) induced by 5-aminolevulinic acid (ALA) or ALA-derivatives or hypericin open new, very interesting perspectives in this therapeutic field.
Jichlinski P et al., 2001-12: Review of bladder-cancer photodynamic therapy describing why the technique never gained wide acceptance, and naming ALA-induced protoporphyrin IX and hypericin as the newer photosensitisers. Methylene blue is not among them. Study type: narrative review. N/A. Country: Switzerland (Geneva). Agents: HPD, ALA/ALA-derivatives (PpIX), hypericin; methylene blue is not among the clinical agents reviewed. Funding/conflicts: not stated. Comparator: none. Bearing CONTRADICTS the claim that methylene blue is a clinical bladder-cancer PDT agent. Study type: review.
